Aim: Mast cell tumours (MCT) are common skin tumours in dogs. If complete surgical removal of the tumours is not possible, then another therapy is needed. In the current study we tested the therapeutic effect of intratumoural injection of interleukin-2 (IL-2).
Materials And Methods: Seven dogs had non-resectable cutaneous MCT. The tumours were injected with 4.5×10(6) IU IL-2.
Results: The early clinical effects in the seven dogs with cutaneous MCT were: complete regression (CR) in two dogs; partial regression (PR) in four, and stable disease (SD) in one dog. The final clinical effects were CR in three dogs, PR in two dogs, and PD in two dogs.
Conclusion: This pilot study shows that intratumoural IL-2 application can exert an anti-MCT effect. A larger study would be required to precisely establish the magnitude of the therapeutic effect against MCT. A single application of IL-2 in cases of non-resectable MCT has no observable side-effects.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Exploring canine mast cell tumors: An investigation into demographic characteristics, and grading system analysis from a pathology lab data (2019-2021).
Prev Vet Med
January 2025
DNAtech, Laboratório Veterinário, Lisboa, Portugal; CECAV, Centro de Ciência Animal e Veterinária, Faculdade de Medicina Veterinária, Universidade Lusófona-Centro Universitário de Lisboa, Portugal; CBIOS - Centro de Investigação em Biociências e Tecnologias da Saúde - Universidade Lusófona, Lisboa, Portugal.
Mast cell tumors (MCT) are among the most common neoplasia in dogs, representing up to 21 % of skin tumors. However, etiology and risk factors for its development remain unclear. This study aimed to reduce this knowledge gap by comprehensively analyzing 905 MCT cases diagnosed in Portugal between 2019 and 2021, using descriptive and inferential analyses.
View Article and Find Full Text PDFClinical differentiation of cutaneous and subcutaneous mast cell tumors in dogs: A pilot study.
Open Vet J
November 2024
Division of Animal Medical Research, Hassen-kai, 2-27 Onozaki, Saito, Miyazaki 881-0012, Japan.
Background: Canine mast cell tumors (MCT) in the skin are classified into cutaneous MCT (cMCT) and subcutaneous MCT (scMCT) types, which exhibit different clinical behaviors. Although these types have been classified only by histology, preoperative differentiation is important for proper surgical planning.
Aim: To examine the accuracy of differentiating these types based on the gross features before surgery.
Immunohistochemical Expression of Programmed Death-Ligand 1 and Cytotoxic T-Lymphocyte Antigen-4 in Canine Cutaneous Mast Cell Tumours.
Vet Comp Oncol
December 2024
Department of Veterinary Clinics, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
Mast cell tumours (MCTs) are the most frequent cutaneous neoplasia of the dog, and they have very variable biological behaviour and survival times. Surgery is still the best treatment, and despite the several adjuvant therapies described, many cases are very aggressive and resistant to these treatments making it urgent to find new therapeutic targets. Nowadays, immunotherapy targeting immune checkpoints has been described as a complementary treatment for several human cancers, but it is still very scarcely studied in veterinary medicine.
View Article and Find Full Text PDFThe Mastocytosis Control Test: A Patient-Reported Outcome Measure Assessing Disease Control.
J Allergy Clin Immunol Pract
December 2024
Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Insititute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
Background: Mastocytosis is characterized by expanding neoplastic mast cells in organs such as the skin, bone marrow, and gastrointestinal tract. The release of mast cell mediators triggers cutaneous, gastrointestinal, and other symptoms. Currently, no validated mastocytosis-specific patient-reported outcome measure (PROM) exists to assess disease control.
View Article and Find Full Text PDFPrognostic significance of YKL-40 expression in canine cutaneous mast cell tumors.
BMC Vet Res
November 2024
Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei, 106319, Taiwan (ROC).
Background: YKL-40, a secretory glycoprotein, is involved in tumor cell proliferation, metastasis, and angiogenesis in human cancers. Its overexpression has been correlated with unfavorable prognosis in many human cancers. In veterinary medicine, elevated YKL-40 levels in the serum of canine cutaneous mast cell tumors (cMCTs) were observed in our previous study.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!